tiprankstipranks
Trending News
More News >
Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
Hong Kong Market

Sinco Pharmaceuticals Holdings Ltd. (6833) Price & Analysis

Compare
0 Followers

6833 Stock Chart & Stats


Financials

6833 FAQ

What was Sinco Pharmaceuticals Holdings Ltd.’s price range in the past 12 months?
Sinco Pharmaceuticals Holdings Ltd. lowest stock price was HK$0.15 and its highest was HK$0.32 in the past 12 months.
    What is Sinco Pharmaceuticals Holdings Ltd.’s market cap?
    Sinco Pharmaceuticals Holdings Ltd.’s market cap is HK$363.89M.
      When is Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date?
      Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date is Aug 27, 2025 which is in 53 days.
        How were Sinco Pharmaceuticals Holdings Ltd.’s earnings last quarter?
        Sinco Pharmaceuticals Holdings Ltd. released its earnings results on Mar 28, 2025. The company reported HK$0.01 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.01.
          Is Sinco Pharmaceuticals Holdings Ltd. overvalued?
          According to Wall Street analysts Sinco Pharmaceuticals Holdings Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Sinco Pharmaceuticals Holdings Ltd. pay dividends?
            Sinco Pharmaceuticals Holdings Ltd. pays a Annually dividend of HK$0.002 which represents an annual dividend yield of 1.12%. See more information on Sinco Pharmaceuticals Holdings Ltd. dividends here
              What is Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate?
              Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Sinco Pharmaceuticals Holdings Ltd. have?
              Sinco Pharmaceuticals Holdings Ltd. has 2,032,890,600 shares outstanding.
                What happened to Sinco Pharmaceuticals Holdings Ltd.’s price movement after its last earnings report?
                Sinco Pharmaceuticals Holdings Ltd. reported an EPS of HK$0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.762%.
                  Which hedge fund is a major shareholder of Sinco Pharmaceuticals Holdings Ltd.?
                  Currently, no hedge funds are holding shares in HK:6833

                  Sinco Pharmaceuticals Holdings Ltd. Stock Smart Score

                  3
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -20.83%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  6.53%
                  Trailing 12-Months
                  Asset Growth
                  2.27%
                  Trailing 12-Months

                  Company Description

                  Sinco Pharmaceuticals Holdings Ltd.

                  Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Sino Biopharmaceutical
                  CSPC Pharmaceutical Group
                  Livzon Pharmaceutical Group
                  Luye Pharma Group
                  3SBio
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis